© 2017 Elsevier Ltd The treatment of some high-incidence human diseases is based on therapeutic cell killing. In cancer this is mainly achieved by chemical drugs that are systemically administered to reach effective toxic doses. As an innovative alternative, cytotoxic proteins identified in nature can be adapted as precise therapeutic agents. For example, individual toxins and venom components, proapoptotic factors, and antimicrobial peptides from bacteria, animals, plants, and humans have been engineered as highly potent drugs. In addition to the intrinsic cytotoxic activities of these constructs, their biological fabrication by DNA recombination allows the recruitment, in single pharmacological entities, of diverse functions of clinical interest such as specific cell-surface receptor binding, self-activation, and self-assembling as nanoparticulate materials, with wide applicability in cell-targeted oncotherapy and theragnosis.
- cancer treatment
- cell-targeted drug delivery
- protein engineering
- recombinant proteins
Serna, N., Sánchez-García, L., Unzueta, U., Díaz, R., Vázquez, E., Mangues, R., & Villaverde, A. (2018). Protein-Based Therapeutic Killing for Cancer Therapies. Trends in Biotechnology, 36(3), 318-335. https://doi.org/10.1016/j.tibtech.2017.11.007